Advanced glycation end products, dementia, and diabetes

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 13, 2014, Pages 4743-4744

  Lovestone, Simon ^a   Smithb, Ulf ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SIRTUIN;

ACETYLATION; DEMENTIA; DIABETES MELLITUS; IMMUNITY; INFLAMMATION; INSULIN SENSITIVITY; METABOLIC DISORDER; METABOLISM; NOTE; PATHOGENESIS; PRIORITY JOURNAL; VASCULAR DISEASE;

ANIMALS; DEMENTIA; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; METABOLIC SYNDROME X; PYRUVALDEHYDE;

EID: 84897517839     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1402277111     Document Type: Note

References (21)

1. Cai W, et al. (2014) Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. Proc Natl Acad Sci USA 111:4940-4945.
2. Park S, Mori R, Shimokawa I (2013) Do sirtuins promote mammalian longevity? A critical review on its relevance to the longevity effect induced by calorie restriction. Mol Cells 35(6):474-480.
3. Kanfi Y, et al. (2012) The sirtuin SIRT6 regulates lifespan in male mice. Nature 483(7388):218-221.
4. Qin W, et al. (2006) Calorie restriction attenuates Alzheimer's disease type brain amyloidosis in Squirrel monkeys (Saimiri sciureus). J Alzheimers Dis 10(4):417-422.
5. Li Y, Xu W, McBurney MW, Longo VD (2008) SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell Metab 8(1):38-48.
6. Kim D, et al. (2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 26(13):3169-3179.
7. Stein TD, Johnson JA (2002) Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci 22(17):7380-7388.
8. Luchsinger JA, Gustafson DR (2009) Adiposity, type 2 diabetes, and Alzheimer's disease. J Alzheimers Dis 16(4):693-704.
9. Killick R, et al. (2009) Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem Biophys Res Commun 386(1):257-262.
10. Lu M, et al. (2013) Neuronal Sirt1 deficiency increases insulin sensitivity in both brain and peripheral tissues. J Biol Chem 288(15):10722-10735.
11. Reddy VP, Zhu X, Perry G, Smith MA (2009) Oxidative stress in diabetes and Alzheimer's disease. J Alzheimers Dis 16(4):763-774.
12. Rodríguez-Martín T, et al. (2013) Tau phosphorylation affects its axonal transport and degradation. Neurobiol Aging 34(9):2146-2157.
13. Götz J, Xia D, Leinenga G, Chew YL, Nicholas H (2013) What renders TAU toxic. Front Neurol 4:72.
14. Piarulli F, Sartore G, Lapolla A (2013) Glyco-oxidation and cardiovascular complications in type 2 diabetes: A clinical update. Acta Diabetol 50(2):101-110.
15. Aude YW, Mego P, Mehta JL (2004) Metabolic syndrome: Dietary interventions. Curr Opin Cardiol 19(5):473-479.
16. Lourida I, et al. (2013) Mediterranean diet, cognitive function, and dementia: A systematic review. Epidemiology 24(4):479-489.
17. Nowlin SY, Hammer MJ, D'Eramo Melkus G (2012) Diet, inflammation, and glycemic control in type 2 diabetes: An integrative review of the literature. J Nutr Metab 2012:542698.
18. Albani D, Polito L, Forloni G (2010) Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: Experimental and genetic evidence. J Alzheimers Dis 19(1):11-26.
19. Harrington C, et al. (2011) Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: Two phase 3 studies. Curr Alzheimer Res 8(5):592-606.
20. Kumar R, et al. (2013) Sirtuin1: A promising serum protein marker for early detection of Alzheimer's disease. PLoS ONE 8(4):e61560.
21. Yao L, et al. (2009) Influence of the Pro12Ala polymorphism of PPAR-gamma on age at onset and sRAGE levels in Alzheimer's disease. Brain Res 1291:133-139.